Compare RIOT & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RIOT | MIRM |
|---|---|---|
| Founded | 2000 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.2B |
| IPO Year | N/A | 2019 |
| Metric | RIOT | MIRM |
|---|---|---|
| Price | $15.30 | $86.64 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 12 | 11 |
| Target Price | $26.13 | ★ $95.64 |
| AVG Volume (30 Days) | ★ 14.4M | 842.5K |
| Earning Date | 02-23-2026 | 02-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 693.97 | N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $637,162,000.00 | $471,794,000.00 |
| Revenue This Year | $78.69 | $53.78 |
| Revenue Next Year | $11.24 | $19.91 |
| P/E Ratio | $37.62 | ★ N/A |
| Revenue Growth | ★ 103.62 | 53.66 |
| 52 Week Low | $6.19 | $36.88 |
| 52 Week High | $23.94 | $83.75 |
| Indicator | RIOT | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 55.45 | 69.69 |
| Support Level | $12.62 | $73.82 |
| Resistance Level | $13.95 | $83.75 |
| Average True Range (ATR) | 0.75 | 3.90 |
| MACD | 0.30 | 0.69 |
| Stochastic Oscillator | 76.23 | 98.63 |
Riot Platforms Inc is a vertically integrated Bitcoin mining company focused on building, supporting, and operating blockchain technologies. The company's segments include Bitcoin Mining and Engineering. The Bitcoin Mining segment generates revenue from the Bitcoin the Company earns through its Bitcoin Mining activities. The Engineering segment generates revenue through customer contracts for custom engineered electrical products. It generates the majority of its revenue from the Bitcoin Mining segment.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.